SM (@StocksMaxi_) header
SM (@StocksMaxi_) profile picture

Chief Mid-Curver | Prev: @Shitcoinmaxi_ | Everything posted is NFA | DYOR Founded @SmResearchLab

Joined January 2025
Photo by SM (@StocksMaxi_)Photo by SM (@StocksMaxi_)Photo by SM (@StocksMaxi_)Photo by SM (@StocksMaxi_)Photo by SM (@StocksMaxi_)Photo by SM (@StocksMaxi_)Photo by SM (@StocksMaxi_)Photo by SM (@StocksMaxi_)Photo by SM (@StocksMaxi_)Photo by SM (@StocksMaxi_)
$IAM picked up a lot of new eyes yesterday with four banks starting coverage. Here’s what you get for ~$665M, with ~$410M of that in cash. The AlphaFold comparison. NeuralPLexer was built with NVIDIA researchers at Caltech. NVIDIA co-owns a patent family and put $25M into the company ~15x faster than AlphaFold 3 by Iambic’s numbers. An independent benchmark clocked the first version at ~100x on the same chip Isomorphic, Alphabet’s AlphaFold drug company, is reportedly raising at ~$50B (Bloomberg) with no drug in humans Iambic, with a drug in 122 patients, is ~$665M. That’s about 1/75th of Isomorphic’s price, and the business beyond cash (~$255M) is under 1/190th, for a model that’s arguably on par on accuracy and ~15x faster by Iambic’s numbers. The drug IAM1363, a HER2 pill, 122 patients dosed. Iambic says it’s the only one known to bind the inactive form of HER2 It concentrates in tumours: 20-30x more drug in the tumour than in the blood, in biopsies from two patients 3 confirmed brain responses in breast cancer patients who’d already failed Enhertu and Tukysa. Nothing is approved for them Registrational trial as early as 2027, and two more drugs entering the clinic The flywheel Molecules designed Monday, made Tuesday, tested by Friday. A traditional pharma design cycle takes weeks to months. Iambic puts ~1,000 molecules through one every 7-10 days, and the CEO puts its pace at ~50x a typical pharma programme Every result goes straight back into the models, so each week’s designs start smarter than the last. More data makes better models, which make better molecules, which make more data That’s how IAM1363 went from programme start to the clinic in under 2 years, with the drug candidate found by month 7. The industry norm is ~6 years Enchant v3: 41B parameters, 4.5T tokens of training data, 6,000+ properties predicted, ~12M predictions a month. Google’s TxGemma tops out at 27B Against TxGemma, by Iambic’s numbers: kinase activity 0.69 vs 0.55, rat clearance 0.70 vs 0.35 With ~5% of the human training data, Enchant matched the best published human PK models trained on 100% The coverage All four of the banks that took Iambic public started coverage on Monday, all at Buy or Overweight Jefferies $35, BofA $30, JPMorgan $22, Citi $22. The average is ~$27, about 95% above $14 BofA’s case: Iambic uses AI to design new drugs, not just to find targets, and it trades below its listed AI peers The stock closed up 31.6% on the day Jefferies has the CEO on its AI drug discovery panel on 18 Nov Commercial validation AbbVie signed up the day Enchant v3 launched: $40M upfront, up to $670M in milestones Bayer’s deal names Enchant and NeuralPLexer. RevMed paid ~$25M for NeuralPLexer alone. Takeda signed a separate technology agreement on top of its drug deal Upfronts keep climbing: $10M (Lundbeck) → $27M (Takeda) → $40M (AbbVie). ~$2.4B in potential milestones across the book Isomorphic’s Lilly and Novartis deals brought $82.5M upfront. Iambic’s bring ~$77M. A similar deal book, at roughly 1/75th of the valuation Last December the CEO told investors more deals were coming. Three signed within nine months. The balance sheet ~$410M pro forma cash, plus AbbVie’s $40M upfront still to come. No debt Funded into late 2028: enough to start the registrational programme for IAM1363 and take two more drugs into the clinic The company is locked up too. No new shares before April without its banks’ sign-off Partner money stretches it further. The CEO says every new deal adds quarters of runway Therefore minimal dillution risk. Who’s buying IPO 5x oversubscribed (Bloomberg) Cathie Wood’s ARK has bought on 8 of 15 days since the IPO, ~2.4M shares across its funds (~5%) Druckenmiller’s Duquesne indicated interest in the IPO A director’s fund bought $11.5M in the IPO. No insider has sold The flow 80% of shares locked until April. The 10 biggest IPO buyers took 80%+ of the rest. Possible Russell add: preliminary list Friday, index buying 11 Dec CEO on Jefferies’ AI drug discovery panel, 18 Nov Of course NFA, Dyor
1
2
2
16
3,834
bio stonking = low cortisol, up only, tons of optimism ahead crypto/ai stonking = max cortisol, stress, musical chairs
469
$ABBV did $17.4B of revenue last quarter. Its Q3 earnings release still made room for one line on $IAM. AbbVie’s own words: programs with “first-in-class and best-in-class potential”, combining Iambic’s platform with AbbVie’s expertise in immunology, neuroscience and oncology. AbbVie paid Iambic $47M upfront in October, and Enchant v3 is already running on the collaboration. A pharma doing $17B a quarter didn’t have to mention a deal this size. It chose to. NFA DYOR
1
1
1
3
1,269
Hyper bullish on iambic
1
6
653
$IAM is priced like the pipeline is an afterthought. At $12.91, ~$175M after cash buys you all of this: The drugs • IAM1363 (HER2): brain tumours shrank in 41% of patients (9/22, incl. unconfirmed), and brain disease was controlled in 21/22. Early, single-arm. Registrational study planned for 2027 • IAM217 (KIF18A): cleared by the FDA for the clinic • IAM-C1 (CDK2/4): Genentech paid $850M upfront for Regor’s CDK drugs in 2024, more than $IAM’s whole market cap The platform • IAM1363 went from program start to the clinic in ~2 years • NeuralPLexer 3 beat AlphaFold 3 on physically valid structures (77.9% vs 73.1%) at ~14x the speed • $NVDA is an investor and co-owns a NeuralPLexer patent family The comps • Isomorphic Labs, reportedly in talks at ~$50B. $IAM after cash is ~1/285th of that • Chai Discovery raised at $3.8B. Recursion and Schrödinger trade at ~$1.8–1.9B each • Partners already paying: AbbVie, Bayer, Takeda, Lundbeck, Revolution Medicines, Jazz The free option The two best-selling drugs of 2025, $LLY’s tirzepatide and Novo’s semaglutide, are peptides that act on GPCRs. Iambic now has peptide data in its model, a GPCR team and metabolic programs. None has been named yet, and you’re paying nothing for them. AI <> Oncology <> Peptides <> Frontier models In one stock. NFA DYOR
$IAM’s first earnings as a public company. The bull case in six lines: • Partners billed $99.8M in 9 months. Running the company cost $107.7M. In Q3, billings beat costs • Peptides are now in the filing, listed as one of Enchant v3’s 16 data types. The IPO prospectus never mentioned them • The FDA cleared a second drug, IAM217, for the clinic. A third IND (IAM-C1) is due this quarter • IAM1363’s registrational study is planned for 2027 • ~$455M of pro forma cash, up from $409M at the IPO • On the preliminary Russell Microcap additions list, effective 11 Dec At $12.91 that’s a ~$630M market cap, so ~$175M for three drugs, eight partnerships and the platform. Peptides and the metabolic programs come free on top. So cheap. No peptide program has been named yet, but the pieces are in place. JPM in January is the first place one could show up. NFA, DYOR
1
3
1,696
$IAM’s first earnings as a public company. The bull case in six lines: • Partners billed $99.8M in 9 months. Running the company cost $107.7M. In Q3, billings beat costs • Peptides are now in the filing, listed as one of Enchant v3’s 16 data types. The IPO prospectus never mentioned them • The FDA cleared a second drug, IAM217, for the clinic. A third IND (IAM-C1) is due this quarter • IAM1363’s registrational study is planned for 2027 • ~$455M of pro forma cash, up from $409M at the IPO • On the preliminary Russell Microcap additions list, effective 11 Dec At $12.91 that’s a ~$630M market cap, so ~$175M for three drugs, eight partnerships and the platform. Peptides and the metabolic programs come free on top. So cheap. No peptide program has been named yet, but the pieces are in place. JPM in January is the first place one could show up. NFA, DYOR
1
1
2
7
1,781
SM retweeted
$IAM these are the results from a company valued at 1/82th of its closest competitor, with a 12x faster AI model, 100% of OPEX already covered by big pharma payments, a 2nd drug advancing to Phase 1, and over 75% of market cap in cash. $PDSB $NAUT
$IAM earnings are out of this world 🔥🚀 We have reached the pivotal point where partners are already funding the OPEX. Last 9 months: $99.8M billed vs. $107.7M of OPEX. Q3: $53.9M billed vs. $41.5M of OPEX. Revenue up 142% YoY. $455M cash. Market cap $580M.
1
2
1
3
1,221
$IAM earnings are out, will be covering later
1
3
806
Something I missed first time round on $IAM, and it backs up my GPCR post. When I posted about the GPCR team, the move beyond cancer was my read of old job ads. It turns out the CEO had already said it. In an interview the week of the IPO, he said Iambic is “actively moving beyond oncology”, and named metabolic disease and endocrinology as part of its own pipeline. Right now all 3 named drugs are cancer drugs. Adding metabolic and endocrine would mean Iambic is no longer a cancer-only bet. The markets are bigger too. Two GLP-1 drugs did ~$73B in sales in 2025. Iambic puts its oncology, metabolic and endocrine discovery work at over $70B. What’s already there: • A GPCR team, hired in late 2025. GPCRs are the receptors Ozempic, Wegovy and Mounjaro work on • Its head trained under Nobel laureate Bob Lefkowitz, runs the non-oncology programs and has worked on metabolic and renal drugs • He presents on Iambic’s GPCR programs on 2 March No non-oncology program has a name yet. When one does, Iambic has a second pipeline next to the cancer one, which gives us a re-rate/catalyst to get excited for.
1
4
1,072
Will keep y’all updated, wish me luck!
7
720
🚨 𝗕𝗥𝗘𝗔𝗞𝗜𝗡𝗚: Michael Carrick has published a very LONG and EMOTIONAL letter to Manchester United fans! ❤️ "Dear United fans, I've had the immense privilege of leading Manchester United, the football club that I love. There are very few who get to live that and feel it, and for that I'm incredibly grateful. With that comes huge responsibility, and to be at Manchester United, you need to understand exactly what that means. It's different to anywhere else. Ultimately, you need to push to be the best, but there is a culture, there are values and there are behaviours that you have to live by and respect, which have been built over a long period of time. It's a football club that is unique, with substance and history that cannot be ignored. This is what inspired me every single day. I want to say a big thank you to the supporters. I must say, you are a special, rare breed. We've had some great times this year and moments we'll all remember. The best thing about being in my position was seeing so many of you lose yourselves in the emotion of those moments, leaving the stadium desperate to come back again next time. I just wanted to give you something back. That love never dies. I know we've not had the results lately, but you've shown me nothing but love and support in times when the easiest thing, and what most end up doing, would be to turn the other way. That means more than a win or two. That's what makes you who you are. That's why I fell in love with this club all those years ago. A special thank you to my coaching staff. You gave me everything you had, every single day, and I couldn't have asked for any more. I'm incredibly grateful for your loyalty, hard work and support throughout. To all the staff behind the scenes, thank you for everything you do for this football club. So much of your work goes unseen, but it never goes unappreciated. And to the players, thank you for your efforts and the moments we've shared. I wish you all the very best for what's ahead. I want nothing but success for Manchester United. This club has been such a big part of my life and that will never change. I'll always be proud to have played my part and I'll always want the very best for it. I'll be right there with you from now on, watching from the sidelines, cheering the lads on." Michael.
80
183
30
1,878
95,044
GET food chained Know your place @realDonaldTrump @USMNT @JDVance
Mauricio Pochettino has agreed to become the Manchester United men’s head coach.

1
593
I spent the last week going through $IAM line by line. S-1 exhibits, job boards, trademark filings, trial registries, the actual partner contracts. Here's what I found that I haven't seen anyone talk about. First, the setup. Iambic is an AI drug discovery company with a real drug in the clinic: IAM1363, a brain-penetrant HER2 pill, 122 patients dosed. It trades around $14–15, roughly a $700M company. Isomorphic (Google DeepMind's drug spinout) is reportedly raising at ~$50B. It has no drug in human trials yet. 1. They're quietly building a GPCR shop GLP-1, GIP and amylin all work through GPCRs. Iambic has been staffing GPCR biology for years: • Head of GPCR Biology since 2024: Will Barnes. Postdoc under Nobel laureate Bob Lefkowitz (the GPCR guy), then Director of Renal & Metabolic Drug Discovery. His public bio says he now leads Iambic's non-oncology programs "from target identification through entry into clinical development." • Oct 2025: they posted a GPCR Biology Director role ($180–240K) to "define and own GPCR biology strategy across one or more programs." • An older GPCR posting described the internal pipeline as "oncology, metabolic, and CNS." • The S-1 lists discovery programs in metabolic disease and endocrinology. • In April, Barnes presented at a GPCR drug discovery summit on using NeuralPLexer + Enchant for "GPCR assets." No metabolic program is named yet. But the people, the hiring and the filings all point the same direction. 2. The partner contracts are attached to the S-1. I read them. • Takeda deal: carves out "Enablement Licenses," letting third parties run Iambic's AI models through a hosted SaaS/API. Their NeuralPLexer trademark is filed for platform-as-a-service. Nobody is modeling a software line. • The Takeda deal also defines "Proximity Inducing Proteins" and "Multi-Protein Targets." That's molecular glue / degrader language. • Lundbeck deal: $10M upfront, Lundbeck pays for the team's work, and Iambic keeps all the collaboration IP plus the right to train its models on the data. Exclusivity covers one target only, so every other GPCR stays open. 3. The board and advisors • Director Shalini Sharp also sits on the boards of Neurocrine and Septerna, two GPCR-focused companies. • Director Kurt von Emster sits on Abingworth/Carlyle's clinical co-development committee. That's capital that funds late-stage trials. • Advisors: Nobel laureate Frances Arnold, Amgen's former head of research Ray Deshaies, NVIDIA's former AI director Anima Anandkumar, and Derek Lowe, pharma's best-known skeptic. 4. The HER2 trial keeps growing The registry target went from 243 patients at 28 sites to 383 patients at 48 sites. You don't expand a trial on a drug you're losing faith in. 5. The money is behind it • Partners: Takeda, AbbVie, Bayer, Lundbeck, Jazz, RevMed. The AbbVie deal announcement called Enchant v3's prediction accuracy "industry-leading." • A director's fund bought $11.5M in the IPO. • ARK bought every dip from Nov 2–6. Why the GPCR angle matters When Septerna signed its oral GPCR obesity deal with Novo ($200M+ upfront and near-term), the stock ran 69% in a day. One deal that size would be $4+ a share in cash for $IAM. What I'm watching • Fri: Russell preliminary additions • Nov 18: CEO on Jefferies' AI drug discovery panel • Dec 9: SABCS (zongertinib breast data, the competitor to watch) • First 10-Q in the next few weeks • Patent publications and new GPCR job posts What could go wrong The confirmed response rate is still maturing (23% in the last cut). There's a big lock-up expiry in April. They'll likely need to raise again by 2027–28. And none of the GPCR work is disclosed yet. This is a read of public breadcrumbs, not a guarantee. But at ~$700M you're getting a clinical HER2 drug, six pharma partners, a 41B-parameter model, and a GPCR team run by a Lefkowitz alum, for under 2% of what Isomorphic is asking with nothing in the clinic. NFA. Do your own work.
Meet $IAM's Head of GPCR Biology 👇 🧬 Trained under Nobel laureate Bob Lefkowitz, the GPCR legend 💊 Before Iambic: Director, Renal & Metabolic Drug Discovery 🎯 Now leads ALL non-oncology programs "through entry into clinical development" 🎤 April talk: NeuralPLexer + Enchant for "GPCR assets" GLP-1's receptor is a GPCR. 👀 NFA
3
1
6
1,760
To add to this, I found some alpha in $IAM’s old job listings, since taken down from its careers page. Iambic has an in-house GPCR drug team. GPCRs are the receptors behind about 1 in 3 FDA-approved drugs, including Ozempic, Wegovy and Mounjaro. In late 2025 Iambic hired a GPCR team: a director-level lead (role now filled), plus scientists screening small molecules against GPCRs, tasked with taking programs “from hit ID through development candidate selection.” Iambic’s Head of GPCR Biology runs its non-oncology programs. His background is in metabolic, renal, liver, respiratory and cardiovascular drugs. Small molecules can be pills. GPCR pills already sell in every area Iambic is linked to: • Obesity: Lilly’s Foundayo (GLP-1 pill) • Hormones: Crinetics’ Palsonify • Migraine: Nurtec, Ubrelvy (Iambic has a migraine deal with Lundbeck) • Immunology: Zeposia (AbbVie and Takeda partner with Iambic here) The prospectus lists Iambic’s own discovery programs in metabolic disease and endocrinology. All 3 of its named drugs are cancer drugs, and none hits a GPCR. If one of those metabolic programs is a GPCR pill, that’s the market Ozempic sells into. Iambic hasn’t said it is. For scale: GLP-1s did ~$73B in 2025, and Novo signed a deal worth up to $2.2B with Septerna for preclinical GPCR obesity pills. No GPCR program has been named yet. But you don’t hire a GPCR team and a Lefkowitz-trained head unless you plan to run GPCR programs. So the call option is: a possible path into commercial medicines like obesity and migraine, on top of the cancer pipeline. NFA
Meet $IAM's Head of GPCR Biology 👇 🧬 Trained under Nobel laureate Bob Lefkowitz, the GPCR legend 💊 Before Iambic: Director, Renal & Metabolic Drug Discovery 🎯 Now leads ALL non-oncology programs "through entry into clinical development" 🎤 April talk: NeuralPLexer + Enchant for "GPCR assets" GLP-1's receptor is a GPCR. 👀 NFA
1
1
2
6
2,228
Will leave this here $IAM
3
1
8
2,507
*what each asset of Iambic is worth if successful / using comps NFA ofc
1
2
250
Fair range would probably be in the low to medium area which aligns with analyst reports. High would be if most goes well
2
199
Two ex-Moderna execs run a fund that has bought $IAM four separate times. Ascenta Capital was founded by Moderna's former CFO, Lorence Kim, and its former Head of Strategy, Evan Rachlin. Both were there for Moderna's $604M IPO. Series B. Series B-3. Convertible notes. Then the IPO at $16. ~$38M in total, about a tenth of their $325M fund. Rachlin also sits on Iambic's board.
1
1
1
10
1,899
What if?
🤖 Made with AI
Michael Carrick and Jensen sacked in one day. Year ruined
2
2
1
10
1,241
Michael Carrick and Jensen sacked in one day. Year ruined
1
1
1
11
3,661